Vanda Pharmaceuticals Inc

Reviva Pharmaceuticals Holdings has implemented a 1-for-20 reverse stock split to boost its share price and avoid a Nasdaq delisting, with a critical compliance deadline of March 27. The company also faces financing challenges for an additional Phase 3 trial of its schizophrenia drug candidate, brilaroxazine.

AT&T (NYSE:T) shares were unchanged after fiber vandalism caused outages in California and Kentucky. The $76 million annual theft cost is a tiny fraction of cash flow, so investors shrugged off the disruption.